eISSN 2508-3589
pISSN 2508-1926

Table. 1.

Table. 1.

Baseline characteristics of 28 patients (28 eyes) who received aflibercept therapy to treat diabetic macular edema

Characteristic Value
Age (years) 61.1 ± 9.4
Sex
Male 18 (64.3)
Female 10 (35.7)
Hypertension 12 (42.9)
Duration of diabetes mellitus (years) 10.2 ± 7.5
Degree of diabetic retinopathy
Non-proliferative 21 (75.0)
Proliferative 7 (25.0)
Hemoglobin A1c* 7.2 ± 1.2
History of treatment for diabetic macular edema 20 (71.4)
Method of prior treatment
Intravitreal bevacizumab 20
Intravitreal bevacizumab plus subtenon TA 5
Intravitreal TA 2
Intravitreal dexamethasone implant 1
Focal laser photocoagulation 1
Best-corrected visual acuity (logMAR) 0.61 ± 0.31
Central retinal thickness (μm) 553.8 ± 144.3

Values are presented as mean ± standard deviation or number (%).

TA = triamcinolone acetonide; logMAR = logarithm of minimal angle of resolution.

*Data from 21 patients with available HbA1c result.

J Retin 2021;6:34-40 https://doi.org/10.21561/jor.2021.6.1.34
© 2021 J Retin